Muscarinic Acetylcholine Receptor M1 (CHRM1)

Muscarinic Acetylcholine Receptor M1 (CHRM1)

Overview

CHRM1 (Muscarinic Acetylcholine Receptor 1), also known as M1 muscarinic receptor, is a G protein-coupled receptor (GPCR) that mediates cholinergic signaling in the central nervous system. The receptor is encoded by the CHRM1 gene located on chromosome 11q12.1 and is predominantly coupled to the Gq/11 signaling pathway. As the most abundant muscarinic receptor subtype in the cortex and hippocampus, M1 receptors play critical roles in learning, memory, attention, and higher cognitive functions[@bonner1991].

The cholinergic system has been central to Alzheimer's disease (AD) research since the seminal "cholinergic hypothesis" proposed in the early 1980s. The discovery of significant loss of cholinergic neurons in the basal forebrain of AD patients led to the development of acetylcholinesterase inhibitors as the first approved treatments for AD symptom management. M1 muscarinic receptors represent a complementary therapeutic target that acts downstream of the cholinergic system, potentially offering cognitive benefits while avoiding some limitations of acetylcholinesterase inhibitors[@coyle1983][@conn2009].

Muscarinic Acetylcholine Receptor M1 (CHRM1)

Overview

CHRM1 (Muscarinic Acetylcholine Receptor 1), also known as M1 muscarinic receptor, is a G protein-coupled receptor (GPCR) that mediates cholinergic signaling in the central nervous system. The receptor is encoded by the CHRM1 gene located on chromosome 11q12.1 and is predominantly coupled to the Gq/11 signaling pathway. As the most abundant muscarinic receptor subtype in the cortex and hippocampus, M1 receptors play critical roles in learning, memory, attention, and higher cognitive functions[@bonner1991].

The cholinergic system has been central to Alzheimer's disease (AD) research since the seminal "cholinergic hypothesis" proposed in the early 1980s. The discovery of significant loss of cholinergic neurons in the basal forebrain of AD patients led to the development of acetylcholinesterase inhibitors as the first approved treatments for AD symptom management. M1 muscarinic receptors represent a complementary therapeutic target that acts downstream of the cholinergic system, potentially offering cognitive benefits while avoiding some limitations of acetylcholinesterase inhibitors[@coyle1983][@conn2009].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">CHRM1 Protein</th></tr>
<tr><td>Protein Name</td><td>Muscarinic acetylcholine receptor M1</td></tr>
<tr><td>Gene</td><td>[CHRM1](/genes/chrm1)</td></tr>
<tr><td>UniProt</td><td>P11229</td></tr>
<tr><td>Chromosome</td><td>11q12.1</td></tr>
<tr><td>Signal Transduction</td><td>Gq/11 → PLC → IP3/DAG → Ca2+/PKC</td></tr>
<tr><td>Primary Location</td><td>Cortex, hippocampus, basal forebrain</td></tr>
<tr><td>Function</td><td>Learning, memory, attention, cognition</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Structure and Molecular Pharmacology

Receptor Structure

CHRM1 is a seven-transmembrane domain GPCR belonging to the class A (rhodopsin) family. The receptor consists of:

• Extracellular N-terminus: Contains glycosylation sites important for proper folding and cell surface expression
• Seven transmembrane helices (TM1-TM7): Form the ligand-binding pocket for acetylcholine and other agonists
• Three extracellular loops (ECL1-ECL3): Participate in ligand binding and selectivity
• Three intracellular loops (ICL1-ICL3): Couple to G proteins and contain regulatory phosphorylation sites
• Intracellular C-terminus: Contains serine/threonine residues for phosphorylation and beta-arrestin recruitment

Signaling Pathways

CHRM1 is predominantly coupled to Gq/11 proteins, initiating the following cascade:

The M1-Gq signaling pathway activates multiple downstream effectors:

• Calcium mobilization: Ca2+ release from ER via IP3 receptors
• PKC activation: Multiple PKC isoforms (α, β, γ)
• MAPK pathways: ERK1/2, p38, JNK activation
• CREB phosphorylation: Transcriptional regulation of memory-related genes
• Ion channel modulation: K+ channel inhibition, NMDA receptor potentiation[@hedrington2018]

Ligand Pharmacology

CHRM1 exhibits distinct pharmacological profiles for different ligand classes:

Agonists:

• Acetylcholine (endogenous agonist)
• Muscarine (mushroom toxin)
• Oxotremorine (synthetic agonist)
• Bethanechol (peripheral selective)
• Cevimeline (FDA-approved for Sjögren's syndrome)

• Atropine (classical antagonist)
• Scopolamine (antimuscarinic)
• Pirenzepine (M1-selective antagonist)
• Telenzepine (M1-selective antagonist)

• BQCA (positive allosteric modulator)
• Benzylidene-quinazolinamines (positive modulators)
• Negative allosteric modulators (various chemotypes)

Distribution and Cellular Expression

Brain Distribution

M1 muscarinic receptors are densely distributed in brain regions critical for cognition:

• Cerebral cortex: Highest density in layers II-III and V, particularly in pyramidal neurons
• Hippocampus: High expression in CA1-CA3 pyramidal cells and dentate gyrus granule cells
• Basal forebrain: Cholinergic neurons express M1 receptors (autoreceptor function)
• Striatum: Medium spiny neurons and interneurons
• Olfactory bulb: Mitral and tufted cells
• Thalamus: Specific relay nuclei

Cellular Localization

Within neurons, M1 receptors are localized to:

• Somatic and dendritic membranes: Postsynaptic sites receiving cholinergic input
• Synaptic spines: Specialization for memory-related signaling
• Dendritic shafts: Integration with other synaptic inputs
• Axon initial segments: Regulation of action potential generation

Role in Cognitive Function

Learning and Memory

M1 muscarinic receptors are essential for various forms of learning and memory:

Hippocampal Synaptic Plasticity

Long-term potentiation (LTP) in the hippocampus, a cellular correlate of learning, requires M1 receptor activity:

• M1 activation enhances NMDA receptor function
• Ca2+ influx through NMDA receptors is potentiated
• PKC activation contributes to LTP maintenance
• CREB-mediated gene transcription supports long-term changes

Cortical Processing

In the cortex, M1 receptors contribute to:

• Attention and vigilance
• Working memory
• Executive function
• Sensory processing integration

Signaling Mechanisms in Memory

The intracellular pathways by which M1 receptors support memory include:

These pathways converge to enhance synaptic strength and support the formation of long-term memory traces.

Role in Alzheimer's Disease

Cholinergic Deficiency in AD

Alzheimer's disease is characterized by progressive degeneration of cholinergic neurons in the basal forebrain:

• Nucleus basalis of Meynert: Major loss of cholinergic projection neurons
• Reduced acetylcholine synthesis: Choline acetyltransferase (ChAT) activity decreased
• Decreased acetylcholine release: Impaired cholinergic neurotransmission
• Reduced muscarinic receptor binding: Both M1 and M2 receptors affected

Amyloid-Tau-Muscarinic Interactions

Aβ pathology interacts with muscarinic receptor signaling in several ways:

Amyloid Effects on M1 Signaling

• Aβ oligomers bind to muscarinic receptors, potentially interfering with ligand binding
• Aβ reduces M1 receptor coupling to Gq proteins
• Aβ-mediated oxidative stress impairs downstream signaling
• M1 receptor activation can protect against Aβ toxicity through anti-apoptotic pathways

Tau Pathology and Cholinergic Dysfunction

• Hyperphosphorylated tau disrupts M1 receptor trafficking to the membrane
• Tau pathology in basal forebrain neurons directly damages cholinergic projections
• M1 receptor activation may protect against tau-induced neurodegeneration

Therapeutic Implications

M1 muscarinic receptor targeting in AD offers several potential benefits:

Symptomatic改善:

• Enhanced cognition through direct receptor activation
• Improved attention and executive function
• Potential reduction of behavioral symptoms

• Neuroprotection against Aβ toxicity
• Anti-inflammatory effects
• Promotion of non-amyloidogenic APP processing
• Protection against tau pathology

Role in Parkinson's Disease

Cholinergic Dysfunction in PD

While primarily considered an extrapyramidal movement disorder, Parkinson's disease involves significant cholinergic dysfunction:

• Basal forebrain cholinergic loss: Cognitive impairment in PD dementia
• Striatal cholinergic interneurons: Dysregulated in PD with motor complications
• Cortical cholinergic denervation: Contributes to executive dysfunction

Levodopa-Induced Dyskinesias

Dyskinesias associated with levodopa treatment involve striatal cholinergic signaling:

• Cholinergic interneurons become overactive in the lesioned striatum
• M1 receptors on these interneurons contribute to dysregulated signaling
• Antimuscarinic drugs (e.g., trihexyphenidyl) reduce dyskinesias but have cognitive side effects

Alpha-Synuclein and Muscarinic Receptors

Alpha-synuclein pathology affects muscarinic receptor function:

• M1 receptor density may be altered in PD brains
• Alpha-synuclein oligomers can interact with muscarinic receptors
• M1 activation may protect against alpha-synuclein toxicity[@espadas2020]

PD Dementia

The cholinergic deficit in PD dementia is more severe than in PD without dementia:

• M1 receptors remain relatively preserved
• M1 agonist therapy may benefit cognitive symptoms
• Combination with dopamine therapy may be beneficial

Other Neurological Disorders

Schizophrenia

M1 receptors are implicated in schizophrenia pathophysiology:

• Reduced M1 receptor density in prefrontal cortex
• M1 agonists may improve cognitive symptoms
• Atypical antipsychotics have M1 activity

Epilepsy

Cholinergic signaling through M1 receptors has anti-epileptic effects:

• M1 activation can reduce seizure activity
• Muscarinic antagonists lower seizure threshold

Multiple Sclerosis

M1 receptors on oligodendrocytes may have roles in myelination:

• M1 activation promotes oligodendrocyte differentiation
• Potential for remyelination therapies

Therapeutic Strategies

Acetylcholinesterase Inhibitors

While not directly targeting M1 receptors, approved AD treatments increase synaptic acetylcholine:

• Donepezil (Aricept): FDA-approved, daily dosing
• Rivastigmine (Exelon): Available as patch and oral
• Galantamine (Razadyne): Allosteric modulator of nicotinic receptors

M1 Selective Agonists

Direct M1 agonist development has faced challenges:

• Coxime (LADDA): Early compound, limited development
• AF267 (Doronine): Showed promise in preclinical models
• Carbachol: Research tool, not clinically used

Positive Allosteric Modulators (PAMs)

PAMs offer a potentially safer approach:

• BQCA: Early development compound
• Benzopyridazines: Advanced PAMs with improved properties
• Pyridine-based PAMs: Novel chemotypes

• Maintain endogenous acetylcholine signaling
• May have better side effect profiles
• Could provide more physiological modulation

M1 Antagonists

While counterintuitive for cognitive enhancement, M1 antagonists have uses:

• Pirenzepine: Research tool, M1-selective
• Use in reducing levodopa-induced dyskinesias
• Treatment of cholinergic excess (some movement disorders)

Research Directions and Knowledge Gaps

Unresolved Questions

Emerging Research Areas

• M1-selective PET ligands: For imaging receptor status in vivo
• Gene therapy approaches: Viral vector delivery of M1 genes
• Novel PAMs with improved brain penetration: Clinical candidates in development
• Combination therapies: M1 agonists with AChEIs or other mechanisms
• Targeted delivery: Nanoparticle approaches to enhance brain uptake

Adverse Effects and Safety Considerations

Peripheral muscarinic side effects limit M1 agonist utility:

• Salivation: Excessive drooling
• Sweating: Diaphoresis
• Gastrointestinal: Nausea, vomiting, diarrhea
• Cardiovascular: Bradycardia, hypotension
• Bronchial: Bronchoconstriction

• Sedation (with high doses)
• Seizures (at very high doses)

• Developing selective compounds
• Using PAMs instead of agonists
• Careful dose titration

Cross-Links and Related Topics

Related Proteins

• [CHRM2 (M2 receptor](/proteins/chrm2-protein)) — Inhibitory muscarinic subtype
• [CHRM3 (M3 receptor](/proteins/chrm3-protein)) — Peripheral muscarinic effects
• [CHRM4 (M4 receptor](/proteins/chrm4-protein)) — Striatal modulation
• [Acetylcholinesterase](/proteins/ache-protein) — AChE inhibitor target
• [Nicotinic receptors](/proteins/nicotinic-receptors) — Ionotropic cholinergic receptors

Related Mechanisms

• [Cholinergic Hypothesis of AD](/mechanisms/cholinergic-hypothesis-ad)
• [Cholinergic Signaling in Neurodegeneration](/mechanisms/cholinergic-signaling-neurodegeneration)
• [Long-term Potentiation](/mechanisms/long-term-potentiation)
• [Amyloid-Beta Toxicity](/mechanisms/amyloid-toxicity)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)

References